Plain-English translation of NCT07678268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether people living with HIV who have stable, undetectable virus levels can do well on a simpler two-drug combination instead of the standard three-drug treatment. Researchers are comparing darunavir/cobicistat plus lamivudine (the simpler option) with darunavir/cobicistat plus tenofovir alafenamide/emtricitabine (the standard three-drug approach). The study will follow participants for 6 to 12 months to see if both treatments keep the virus suppressed and which is easier to live with.
Simpler HIV regimens with fewer pills may be easier to take consistently and may reduce side effects, but doctors need solid evidence that they work just as well as standard three-drug combinations in people whose virus is already under control.
You likely qualify if…
You likely don't qualify if…
If you join, you will either continue taking your current two-drug combination or switch to the three-drug combination, as determined by the study. You'll visit the clinic at weeks 24 and 48 to have your blood drawn to check that your virus stays suppressed and to monitor how well you're tolerating the medication. The study takes place over 6 to 12 months, with regular blood tests to make sure everything is working as expected.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Mexico